Clinical trials: Disorder of the Lower Urinary Tract
Urge Urinary Incontinence, Overactive Bladder
Anticholinergic vs. Botox Comparison Study
Urinary incontinence is a prevalent condition that markedly impacts quality of life and disproportionately affects women. Overactive Bladder syndrome (OAB) is defined as symptoms of urgency and frequency with urge urinary…
- Trial name
- ABC (NCT01166438)
- Testing
- Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg
- Where
- 11 sites in United States
- Volunteers
- 249 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Urinary Incontinence
Adjustable Continence Therapy (ACT) Device for the Treatment of Female Stress Urinary Incontinence
The purpose of this study is to evaluate the safety and effectiveness of a minimally invasive surgical procedure in up to 160 implanted female patients in which two adjustable balloons (one on each side of the urethra) are…
- Trial name
- ACT (NCT00113555)
- Testing
- ACT (Adjustable Continence Therapy)
- Where
- 7 sites in United States, Canada
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Uromedica
Prolapse, Urinary Incontinence
Long-term Effectiveness of Abdominal Sacrocolpopexy for the Treatment of Pelvic Organ Prolapse
The Colpopexy and Urinary Reduction Effort (CARE) trial is a research study designed to evaluate whether the addition of a second surgical procedure in addition to a procedure for female pelvic organ prolapse (POP) affects the…
- Trial name
- E-CARE (NCT00099372)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Urge Urinary Incontinence, Overactive Bladder
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo.
- Trial name
- BRIDGES (NCT00862745)
- Testing
- Fesoterodine
- Where
- 13 sites in United States
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Urinary Bladder, Overactive
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB).
- Trial name
- NCT01314872
- Testing
- Vibegron, Tolterodine ER
- Volunteers
- 1,395 people
- Sponsor
- Merck Sharp & Dohme LLC
Stress Urinary Incontinence
Effect of Peri-Urethral Stimulation on Intra-Urethral Pressure
The purpose of this early feasibility prospective study is to gain initial understanding of the effect of acute peri-urethral neurostimulation on the perineal nerves on intra-urethral pressure.
- Trial name
- NCT05900570
- Testing
- Urodynamic testing with and without pudendal nerve stimulation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Corewell Health East
Overactive Bladder, Urinary Incontinence
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00915525
- Testing
- botulinum toxin Type A
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 829 people
- Sponsor
- Allergan
Overactive Bladder Syndrome, Urinary Incontinence, Urge
Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence
This study is designed to evaluate whether bilateral Posterior Tibial Nerve Stimulation is more effective than unilateral Posterior Tibial Nerve Stimulation at treating overactive bladder and urge urinary incontinence
- Trial name
- BUTTON (NCT03535857)
- Testing
- PTNS
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Gnankang Sarah Napoe
Stress Urinary Incontinence
A Post-Market Study of the AMS AdVance™ Male Sling System for the Treatment of Male Stress Urinary Incontinence
A prospective, multi-center study of the AdVance Male Sling for Stress Urinary Incontinence. The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical…
- Trial name
- NCT00998790
- Testing
- American Medical Systems (AMS) AdVance™ Male Sling System
- Where
- 3 sites in Belgium, France
- Volunteers
- 114 people
- Sponsor
- Boston Scientific Corporation
Overactive Bladder
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.
- Trial name
- NCT00658684
- Testing
- fesoterodine fumarate
- Where
- 12 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Pfizer
Overactive Bladder
Fesoterodine Flexible Dose Study
This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence…
- Trial name
- NCT00536484
- Testing
- Fesoterodine
- Where
- 95 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer
Urologic Diseases, Urinary Bladder, Overactive
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of…
- Conditions
- Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases
- Trial name
- BEYOND (NCT01638000)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 217 sites in Armenia, Austria and 31 more
- Volunteers
- 1,887 people
- Sponsor
- Astellas Pharma Europe Ltd.
Pelvic Organ Prolapse
The Extended Operations And Pelvic Muscle Training In The Management Of Apical Support Loss Study
Women will be invited to participate in E-OPTIMAL at their last clinical follow-up visit for OPTIMAL (at 24 months post surgery).
- Trial name
- E-OPTIMAL (NCT01166373)
- Testing
- Enrollment video, SSLF, ULS
- Where
- 7 sites in United States
- Volunteers
- 285 people
- Sponsor
- NICHD Pelvic Floor Disorders Network
Urinary Incontinence, Stress
A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence
The purpose of this study is to obtain surgical technique data for use in physician education and training and to collect early clinical outcomes data for future publication.
- Trial name
- AMS051 (NCT00904969)
- Testing
- The AMS Male Transobturator Sling System, AdVance Male Sling
- Where
- 11 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- American Medical Systems
Urinary Bladder Diseases, Urinary Bladder Overactive
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence…
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
- Trial name
- BESIDE (NCT01908829)
- Testing
- mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg
- Where
- 219 sites in United States, Armenia and 29 more
- Volunteers
- 2,174 people
- Sponsor
- Astellas Pharma Europe Ltd.
Detrusor Overactivity, Multiple Sclerosis
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in reducing the daily number of episodes on incontinence.
- Trial name
- NCT00678795
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Jazz Pharmaceuticals
Urinary Bladder, Overactive
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active…
- Trial name
- TAURUS (NCT00688688)
- Testing
- Mirabegron, Tolterodine
- Where
- 308 sites in United States, Australia and 28 more
- Volunteers
- 2,792 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive
Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive Bladder
This is an open-label extension study intended for subjects who have previously completed study A0221045 (fesoterodine in elderly OAB patients) and who have been recommended by the investigator as being suitable for the extended…
- Trial name
- NCT01054222
- Testing
- Fesoterodine
- Where
- 3 sites in Portugal
- Volunteers
- 31 people
- Sponsor
- Pfizer
Urinary Incontinence
DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence
This study will explore the safety, tolerability and efficacy of litoxetine in men and women who suffer from urinary incontinence
- Trial name
- NCT03397771
- Testing
- Litoxetine
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Ixaltis SA
Urinary Bladder, Overactive, Urinary Incontinence
Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence
This study will evaluate the efficacy and safety of onabotulinumtoxinA 100 U (BOTOX®), compared to placebo, when injected into the bladder using an alternative injection paradigm in reducing the number of daily urinary…
- Trial name
- LO-BOT (NCT03052764)
- Testing
- onabotulinumtoxinA
- Where
- 31 sites in United States
- Volunteers
- 120 people
- Sponsor
- Allergan